Current Status (2026) Retatrutide remains under clinical investigation and is progressing through large Phase 3 trials for obesity and related metabolic conditions
J Neurosci 31(17):65876594 Hansen HH, Barkholt P, Fabricius K, Jelsing J, Terwel D, Pyke C, Knudsen LB, Vrang N (2016) The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy
2024;26(Suppl 4):1627
This reduction in calorie intake, and subsequent weight loss, is believed to be caused by a decrease in appetite and cravings and a reduction in cravings for high-fat foods
Heres why these patches dont work and how real GLP-1 treatments approved by the FDA actually deliver meaningful weight loss results
When meals lean heavily on quick-digesting carbs, blood sugar spikes then crashes and your brain is already scanning the kitchen for its next target